| Literature DB >> 33649153 |
Kam Ying Wong1, Bethan Davies2, Yewande Adeleke1, Thomas Woodcock1, Dionne Matthew3, Sara Sekelj4, Andi Orlowski1,4, Bradley Porter5,6, Sophia Hashmy7, Ammu Mathew2, Ron Grant8, Agnes Kaba2, Brigitte Unger-Graeber9, Bruno Petrungaro4, Jordan Wallace10, Derek Bell1, Martin R Cowie11, Sadia Khan12.
Abstract
OBJECTIVE: Atrial fibrillation (AF) is the most common arrhythmia. Undiagnosed and poorly managed AF increases risk of stroke. The Hounslow AF quality improvement (QI) initiative was associated with improved quality of care for patients with AF through increased detection of AF and appropriate anticoagulation. This study aimed to evaluate whether there has been a change in stroke and bleeding rates in the Hounslow population following the QI initiative.Entities:
Keywords: atrial fibrillation; electrocardiography; quality of health care; stroke; translational medical research
Year: 2021 PMID: 33649153 PMCID: PMC7925241 DOI: 10.1136/openhrt-2020-001558
Source DB: PubMed Journal: Open Heart ISSN: 2053-3624
Figure 1Proposed impact model with a level change for the ITS analysis. Red solid line=preintervention trend; red dashed line=counterfactual; blue line=postintervention trend; β0=intercept representing starting level of outcome variable; β1=slope prior to intervention; β2=change in level after intervention; T=time since start of the study; X=intervention. ITS, interrupted time series.
Mean monthly expected AF prevalent population, mean monthly incidence (sex-stratified and age group-stratified incidence) and mean monthly age-standardised and sex-standardised rate for each measure, in Hounslow CCG from 2011 to 2018
| 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | |
| Expected AF prevalent population (mean (SD)) | 3996.0 (103.0) | 4143.3 (98.4) | 4316.1 (100.3) | 4478.3 (104.8) | 4617.7 (105.7) | 4757.2 (105.3) | 4911.6 (116.4) | 5014.4 (132.5) |
| Incidence (mean (SD)) | 33.5 (5.9) | 32.3 (4.67) | 33.6 (3.7) | 36.2 (6.7) | 35.8 (6.2) | 35.1 (4.9) | 42 (5.6) | 37.4 (5.2) |
| Sex (n (%)) | ||||||||
| Male | 17.3 (51.5) | 19.3 (59.7) | 16.0 (47.6) | 20.8 (57.4) | 21.5 (60) | 21.3 (60.6) | 23.8 (56.7) | 20 (54.8) |
| Female | 16.3 (48.5) | 13.0 (40.3) | 17.6 (52.4) | 15.4 (42.6) | 14.3 (40) | 13.8 (39.4) | 18.2 (43.3) | 16.9 (45.2) |
| Age group (n (%)) | ||||||||
| 0–17 | 0.2 (0.5) | 0.1 (0.3) | 0.2 (0.5) | 0.8 (2.3) | 0.4 (1.2) | 0.1 (0.2) | 0.1 (0.2) | 0.0 (0.0) |
| 18–64 | 10.0 (29.9) | 8.5 (26.3) | 8.3 (24.6) | 9.3 (25.6) | 11.1 (30.9) | 11.3 (32.3) | 14.0 (33.3) | 10.4 (27.8) |
| >65 | 23.3 (69.7) | 23.7 (73.4) | 25.2 (74.9) | 26.1 (72.1) | 24.3 (67.9) | 23.7 (67.5) | 27.9 (66.5) | 27.0 (72.2) |
| Standardised rate (per 100 000) (mean (SD)) | 797.3 (179.2) | 776.2 (115.9) | 762.0 (79.2) | 786.1 (154.1) | 729.5 (190.6) | 739.2 (96.6) | 858.9 (110.1) | 747.7 (87.7) |
| Incidence (mean (SD)) | 7.7 (0.5) | 7.5 (0.7) | 9.3 (0.6) | 8.7 (1.9) | 7.8 (2.2) | 6.4 (0.8) | 8.4 (0.6) | 8.5 (0.7) |
| Sex (n (%)) | ||||||||
| Male | 2.9 (38.0) | 4.0 (53.3) | 4.0 (43.2) | 4.4 (51.0) | 3.8 (48.4) | 3.4 (53.3) | 5.0 (59.4) | 4.0 (47.1) |
| Female | 4.8 (62.0) | 3.5 (46.7) | 5.3 (56.8) | 4.3 (49.0) | 4.0 (51.6) | 3.0 (46.8) | 3.4 (40.6) | 4.5 (52.9) |
| Age group (n (%)) | ||||||||
| 0–17 | 0.0 (0) | 0.0 (0) | 0.0 (0) | 0.0 (0) | 0.0 (0) | 0.0 (0) | 0.0 (0) | 0.0 (0) |
| 18–64 | 0.4 (5.4) | 1.2 (15.6) | 0.9 (9.9) | 0.9 (10.6) | 0.9 (11.8) | 0.8 (13.0) | 1.5 (17.8) | 1.8 (21.6) |
| >65 | 7.3 (94.6) | 6.3 (84.4) | 8.3 (90.1) | 7.8 (89.4) | 6.8 (88.2) | 5.6 (87.0) | 6.9 (82.2) | 6.7 (78.4) |
| Standardised rate (per 100 000) (mean (SD)) | 32.1 (2.4) | 30.1 (2.7) | 35.8 (2.3) | 32.3 (7.2) | 28.2 (8.4) | 22.6 (2.8) | 28.7 (1.9) | 29.0 (2.3) |
| Incidence (mean (SD)) | 3.25 (0.4) | 2.7 (0.9) | 3.8 (0.5) | 3.6 (0.1) | 3.4 (0.8) | 4.7 (0.3) | 6.3 (0.9) | 4.8 (0.2) |
| Sex (n (%)) | ||||||||
| Male | 1.8 (56.4) | 1.2 (43.8) | 2.2 (56.5) | 2.3 (62.8) | 2.1 (61.0) | 2.9 (62.5) | 4.3 (67.1) | 3.0 (62.1) |
| Female | 1.4 (43.6) | 1.5 (56.3) | 1.7 (43.5) | 1.3 (37.2) | 1.3 (39.0) | 1.8 (37.5) | 2.1 (32.9) | 1.8 (37.9) |
| Age group (n (%)) | ||||||||
| 0–17 | 0.0 (0.0) | 0.0 (0.0) | 0.0 (0.0) | 0.0 (0.0) | 0.0 (0.0) | 0.0 (0.0) | 0.0 (0.0) | 0.0 (0.0) |
| 18–64 | 0.3 (10.3) | 0.2 (6.3) | 0.3 (6.5) | 0.1 (2.3) | 0.1 (2.4) | 0.3 (7.1) | 0.5 (7.9) | 0.2 (3.4) |
| >65 | 2.9 (89.7) | 2.5 (93.8) | 3.6 (93.5) | 3.5 (97.7) | 3.3 (97.6) | 4.3 (92.9) | 5.8 (92.1) | 4.7 (96.6) |
| Standardised rate (per 100 000) (mean (SD)) | 13.6 (1.3) | 10.7 (3.9) | 14.8 (1.9) | 13.2 (0.5) | 12.3 (3.0) | 16.3 (0.1) | 21.3 (3.0) | 16.0 (1.5) |
| Incidence (mean (SD)) | 2.2 (0.5) | 1.0 (0.2) | 2.8 (0.4) | 2.8 (0.7) | 3.3 (0.4) | 2.9 (0.4) | 5.3 (0.4) | 4.7 (0.5) |
| Sex (n (%)) | ||||||||
| Male | 1.3 (57.7) | 0.4 (41.7) | 1.9 (67.6) | 1.8 (64.7) | 1.9 (59.0) | 1.3 (45.7) | 3.6 (68.3) | 3.5 (75.0) |
| Female | 0.9 (42.3) | 0.6 (58.3) | 0.9 (32.4) | 1.0 (35.3) | 1.3 (41.0) | 1.6 (54.3) | 1.7 (31.8) | 1.2 (25.0) |
| Age group (n (%)) | ||||||||
| 0–17 | 0.0 (0.0) | 0.0 (0.0) | 0.0 (0.0) | 0.0 (0.0) | 0.0 (0.0) | 0.0 (0.0) | 0.0 (0.0) | 0.2 (3.6) |
| 18–64 | 0.2 (7.7) | 0.1 (8.3) | 0.4 (14.7) | 0.5 (17.6) | 0.3 (10.3) | 0.2 (5.7) | 0.8 (14.3) | 0.5 (10.7) |
| >65 | 2 (92.3) | 0.9 (91.7) | 2.4 (85.3) | 2.3 (82.4) | 2.9 (89.7) | 2.8 (94.3) | 4.5 (85.7) | 4.0 (85.7) |
| Standardised rate (per 100 000) (mean (SD)) | 9.1 (0.1) | 4.0 (1.0) | 10.9 (0.0) | 10.5 (2.7) | 11.7 (1.4) | 10.3 (1.3) | 17.6 (1.1) | 14.7 (0.9) |
Estimated effects (IRR) of the intervention variable in the unadjusted and seasonality adjusted ITS level change models
| Intervention (level change) | ||||||
| Unadjusted | Seasonality adjusted | |||||
| IRR | 95% CI | P value | IRR | 95% CI | P value | |
| Measure 1 | 0.83 | 0.731 to 0.958 | <0.010** | 0.83 | 0.712 to 0.963 | <0.014* |
| Measure 2 | 0.74 | 0.555 to 0.993 | <0.045* | 0.75 | 0.550 to 1.025 | <0.071 |
| Measure 3 | 0.94 | 0.618 to 1.417 | <0.755 | 0.93 | 0.597 to 1.449 | <0.749 |
| Measure 4 | 0.93 | 0.569 to 1.502 | <0.751 | 0.92 | 0.520 to 1.621 | <0.769 |
Measure 1: admission with stroke as primary diagnosis
Measure 2: admission with stroke as primary diagnosis and AF as secondary diagnosis
Measure 3: admission with bleeding as primary diagnosis and AF in any position of diagnosis.
Measure 4: admission with bleeding as primary diagnosis and use of OAC as secondary diagnosis
*P<0.05, **p<0.01
AF, atrial fibrillation; IRR, incidence rate ratio; ITS, interrupted time series; OAC, oral anticoagulation.
Figure 2Seasonality adjusted ITS regression showing age-sex-standardised rate of admission with stroke as primary diagnosis in Hounslow CCG from January 2011 to August 2018. Grey vertical line: Intervention time point. Level change in relation to intervention variable: IRR 0.83; 95% CI 0.721 to 0.963; p<0.014. AF, atrial fibrillation; CCG, Clinical Commissioning Group; IRR, incidence rate ratio; ITS, interrupted time series.
Figure 3Seasonality adjusted ITS regression showing age-sex-standardised rate of admission with stroke as primary diagnosis and AF as secondary diagnosis in Hounslow CCG from January 2011 to August 2018. Grey vertical line: Intervention time point. Level change in relation to intervention variable: IRR 0.75; 95% CI 0.550 to 1.025; p<0.071. AF, atrial fibrillation; CCG, Clinical Commissioning Group; IRR, incidence rate ratio; ITS, interrupted time series.
Figure 4Seasonality adjusted ITS regression showing age-sex-standardised rate of admission with bleeding as primary diagnosis and AF in any position of diagnosis in Hounslow CCG from January 2011 to August 2018. Grey vertical line: Intervention time point. Level change in relation to intervention variable: IRR 0.93; 95% CI 0.597 to 1.449; p<0.749. AF, atrial fibrillation; CCG, Clinical Commissioning Group; IRR, incidence rate ratio; ITS, interrupted time series.
Figure 5Seasonality adjusted ITS regression showing age-sex-standardised rate of admission with bleeding as primary diagnosis and use of OAC as secondary diagnosis in Hounslow CCG from January 2011 to August 2018. Grey vertical line: intervention time point. Level change in relation to intervention variable: IRR 0.92; 95% CI 0.520 to 1.621; p<0.769. CCG, Clinical Commissioning Group; IRR, incidence rate ratio; ITS, interrupted time series; OAC, oral anticoagulation.